Synopsis Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. The primary purpose of this study was to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease. This week’s “MED FACT” discusses a clinical trial from The Lancet, “ Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial”.
Authors: Sonia S Anand et.al. Key Takeaways: Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Objective: To evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban…
